In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

Leerink analysts warned that Kennedy’s remarks to FDA staff would likely be a negative for the biotech industry.

Vanda is criticizing the FDA’s restrictions on information companies can provide regarding off-label use of approved ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

Future Pak—which was rejected by Vanda Pharmaceuticals last summer—is offering to buy Theratechnologies for an unsolicited ...

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...